Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 463

The DOI matches its Crossref record.

Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union

Open access
Ylä-Herttuala, Seppo·2012·Molecular Therapy

Abstract

In an Editorial published earlier this year in Molecular Therapy,1Ylä-Herttuala S The need for increased clarity and transparency in the regulatory pathway for gene medicines in the European Union.Mol Ther. 2012; 20: 471-472Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar I described the regulatory uncertainty surrounding the evaluation of Glybera (alipogene tiparvovec) by the European Medicines Agency (EMA). Glybera is an adeno-associated viral vector engineered to express lipoprotein lipase in the muscle for the treatment of lipoprotein lipase deficiency. As with a typical TV serial, its regulatory saga has now had four acts, leading recently to a final recommendation by the EMA to approve Glybera in the European Union.2European Medicines Agency. Press release: European Medicines Agency recommends first gene therapy for approval http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/07/news_detail_001574.jsp&mid=WC0b01ac058004d5c1 20 July 2012Google Scholar Although this is excellent news for the gene and cell therapy communities and for companies working in this area, the regulatory process that led to this positive outcome is still not without problems. Amsterdam Molecular Therapeutics submitted its original application to the EMA in January 2010. The specialty Committee of Advanced Therapies (CAT), established by the EMA to review gene and cell therapy products, recommended against a marketing authorization for Glybera, and this view was consequently adopted by the Committee on Human Medicinal Products (CHMP), which makes final recommendations for marketing authorization in the EU. Amsterdam Molecular Therapeutics responded by requesting reexamination of the application, which led to the CAT's reversing its earlier ruling and recommending approval of the drug. It was therefore a great surprise when, in October 2011, the CHMP once again rejected marketing authorization based on its view that “the dossier had not provided sufficient evidence of a persistence of effect in lowering blood fats in a clinically relevant manner and there were too few patients from whom sufficiently long-term data were available.” Indeed, lipoprotein lipase deficiency is an ultra-orphan disease affecting only one in a million people. According to publicly available information, the clinical results were based on only 27 patients. Following the negative decision, Amsterdam Molecular Therapeutics faced severe financial problems, and a new private company (UniQure) was established with rights to Amsterdam Molecular Therapeutics’ assets. Apparently after intensive lobbying and some political pressure, in January 2012 the European Commission, which usually ratifies CHMP recommendations, unexpectedly asked the committee to reexamine Glybera for an indication restricted to lipoprotein lipase–deficient patients who have experienced either severe or multiple pancreatitis attacks, which are serious problems in these patients. Further analysis showed that patients receiving Glybera experienced significantly fewer pancreatitis attacks than they had before treatment. The third review resulted in a CHMP vote of 16 to 15 in favor of marketing authorization—1 vote shy of the absolute majority (in this case 17) necessary for a positive opinion. Thus, the third round of review produced a negative opinion, even though a narrow majority on the CHMP was in favor of approval. Evaluation of Glybera for the restricted indication had limited the clinical material to 12 patients, and the CHMP was concerned that the data showing a reduction in postprandial plasma chylomicrons was apparently derived from only 5 patients. Recognizing “the difficulty of obtaining data in this rare disease,” the CHMP invited UniQure to request reexamination for a fourth time, which resulted in the CHMP's handing down a majority vote on 19 July in favor of authorization. Apparently, the CHMP concluded that the benefits of Glybera in this subset of patients were greater than the known risks. This positive decision should be ratified by the European Commission later this year. This lengthy and tortuous approval process raises several questions. Frequent reapplications are very time-consuming and expensive, which in this case led to the demise of Amsterdam Molecular Therapeutics, although thankfully private investors were able to continue the process. Nevertheless, investors will shy away from supporting biotech companies unless greater clarity and predictability can be achieved in the process of regulatory evaluation and approval. The Glybera saga also highlights problems specific to ultra-orphan drugs—because obtaining large-scale phase III data with a very limited number of patients is virtually impossible, procedures to handle these indications must be further developed. Reapplications are not entirely uncommon during the regulatory evaluation of traditional small-molecule drugs and monoclonal antibodies. However, it is noteworthy that t

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2012.194

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 463

Metadata

Authors
Ylä-Herttuala, S.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2012-10
Volume
20
Issue
10
Pages
1831-1832
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2071404720
Cited by
463
References
0
FWCI
20.02
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union. https://app.cochat.ai/papers/10.1038/mt.2012.194
The paper
Ylä-Herttuala, S. (2012). Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union. Molecular Therapy. https://doi.org/10.1038/mt.2012.194

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.